MarketPulse

Phase III studies

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Ultragenyx Faces Securities Lawsuit Over Misleading Drug Efficacy Claims

Securities class action filed against $RARE for allegedly misrepresenting setrusumab efficacy data. Investors may claim damages; lead plaintiff deadline April 6, 2026.
RAREsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

RARE Stock Plunges 42% on Failed Trials; Securities Fraud Lawsuit Filed

Ultragenyx Pharmaceutical faces securities fraud lawsuit after setrusumab trials failed. Stock crashed 42% in December; investors have until April 6, 2026, to join action.
RAREsecurities fraudclass action lawsuit